Business Description
ABVC BioPharma Inc
NAICS : 325412
SIC : 2834
ISIN : US00091F3047
Total Employee Number:
19Description
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 57.4 | |||||
3-Year EPS without NRI Growth Rate | 59.1 | |||||
3-Year FCF Growth Rate | 60.4 | |||||
3-Year Book Growth Rate | -21.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.39 | |||||
9-Day RSI | 38.44 | |||||
14-Day RSI | 43.97 | |||||
3-1 Month Momentum % | -13.77 | |||||
6-1 Month Momentum % | -43.33 | |||||
12-1 Month Momentum % | -70.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.12 | |||||
Quick Ratio | 0.12 | |||||
Cash Ratio | 0.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -94.9 | |||||
Shareholder Yield % | 0.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -93.03 | |||||
ROA % | -46.33 | |||||
ROIC % | -40.7 | |||||
3-Year ROIIC % | 63.92 | |||||
ROC (Joel Greenblatt) % | -73.94 | |||||
ROCE % | -71.65 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.14 | |||||
Price-to-Tangible-Book | 3.14 | |||||
EV-to-EBIT | -4.48 | |||||
EV-to-Forward-EBIT | 3.01 | |||||
EV-to-EBITDA | -4.74 | |||||
EV-to-Forward-Revenue | 1256.92 | |||||
EV-to-FCF | -11.88 | |||||
Price-to-GF-Value | 1.55 | |||||
Earnings Yield (Greenblatt) % | -22.32 | |||||
FCF Yield % | -9.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABVC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ABVC BioPharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.39 | ||
| Beta | 0.5478 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 69.59 | ||
| 14-Day RSI | 43.97 | ||
| 14-Day ATR ($) | 0.193978 | ||
| 20-Day SMA ($) | 1.518 | ||
| 12-1 Month Momentum % | -70.03 | ||
| 52-Week Range ($) | 0.8801 - 4.045 | ||
| Shares Outstanding (Mil) | 26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ABVC BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ABVC BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-03 | In 112 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 30 days | ||
| First quarter earnings results for 2026 | 2026-05-18 | 1.10 (+1.85%) | ||
| Annual report for 2025 | 2026-04-03 | 1.09 (+2.83%) | ||
| General meeting for 2026 | 2026-03-26 10:00 | 1.08 (-2.70%) | ||
| Third quarter earnings results for 2025 | 2025-11-03 | 2.80 (-2.78%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 2.94 (+0.68%) | ||
| General meeting for 2025 | 2025-06-03 10:00 | 1.54 (+11.59%) | ||
| First quarter earnings results for 2025 | 2025-04-30 | 1.03 (+1.98%) | ||
| Annual report for 2024 | 2025-04-15 | 0.92 (-3.13%) |
Show
Entries
ABVC BioPharma Inc Frequently Asked Questions
What is ABVC BioPharma Inc(ABVC)'s stock price today?
The current price of ABVC is $1.35. The 52 week high of ABVC is $4.05 and 52 week low is $0.88.
When is next earnings date of ABVC BioPharma Inc(ABVC)?
The next earnings date of ABVC BioPharma Inc(ABVC) is 2026-08-13 Est..
Does ABVC BioPharma Inc(ABVC) pay dividends? If so, how much?
ABVC BioPharma Inc(ABVC) does not pay dividend.
Guru Commentaries on NAS:ABVC
No articles.
Press Release
Articles on ABVC BioPharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers